HAE: who owns it, and who’s predicted to buy next
Haemonetics Corp/Mass · Health Care · on the Prior Moves forward board for 2026-09-30 at rank #21. Research, not investment advice.
Predicted to buy next quarter
3 tracked investors are included in the model-ranked expectations for HAE in 2026-09-30. This is a forecast about a later filing, not a confirmation that anyone has bought the security or a recommendation to do so.
- Lee Ainslie · Maverick
- Chuck Akre · Akre Capital
- Brad Gerstner · Altimeter
Strongest ranked investor signal: Egerton. No calibrated purchase probability is shown.
Currently disclosed holders
No investor in our tracked set discloses HAE in their latest 13F. The prediction above is a forward call, not a mirror of current holdings.
Mutual fund and ETF holders
200 US mutual funds and ETFs from 101 fund families reported a position in HAE for the quarter ending 2026-06-30. Against their own report a quarter earlier, 76 raised shares, 15 opened a new position, 65 cut and 16 sold out. Source: SEC Form N-PORT, which funds file about 60 days after quarter end. Share counts, not trades: a change can reflect fund inflows rather than a decision about HAE.
| Fund family | Funds | Share of fund-held shares |
|---|---|---|
| Vanguard Index Funds | 5 | 26.7% |
| Ishares Trust | 11 | 26.6% |
| Ariel Investment Trust | 2 | 5.6% |
| Touchstone Strategic Trust | 1 | 4.5% |
| Allspring Funds Trust | 2 | 4.3% |
| Spdr Series Trust | 7 | 2.5% |
| Aqr Funds | 13 | 2.5% |
| Bridge Builder Trust | 3 | 2.2% |
The predicted next buys, fresh disclosures, and the week’s catalysts. One email a week. Honest numbers, never advice.
See the full ranked board on top picks, how the PriorScore is built on how it works, the honest edge numbers on methodology, and the running accuracy on the prediction leaderboard. Forward quarter 2026-09-30, data as of 2026-10-16. Research, not investment advice, see the disclaimer.